Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
Current standard treatment for locally advanced cervical cancer is cisplatin-based concurrent
chemoradiation (CRT). Although recently reported meta-analysis studies also demonstrated
improved local control rates and survival with cisplatin-based chemotherapy concurrent to
radiation therapy (RT), the optimal cisplatin dose and dosing schedule are still
undetermined.
In light of the results of the previous clinical trial, weekly cisplatin 40 mg/m2 considered
to be a standard regiment in cisplatin doses and dosing schedules. However, our randomized
phase II trial showed that tri-weekly cisplatin 75mg/m2 has lower toxicities and a better
outcome in locally advanced cervical cancer.
In this randomized phase III trial, the investigators investigate that there may be a
survival difference between weekly cisplatin 40 mg/m2 and tri-weekly cisplatin 75 mg/m2
administration concurrent to RT in cervical cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Korea Cancer Center Hospital
Collaborators:
Asan Medical Center Gangnam Severance Hospital Seoul National University Hospital